Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Liwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-1666-4058; OpenAlex author ID A5118519954. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Co-author DOI 10.1016/j.xcrm.2025.101928↗
  2. The Role of Bile Acids in Pancreatic Cancer. Last author DOI 10.2174/0115680096281168231215060301↗
  3. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. Last author DOI 10.1049/syb2.12068↗
  4. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3390/ijms24010156↗
  5. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  6. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  7. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗
  8. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2012.04.014↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiebo Mao · 4 shared papers, 2022–2025 · strength 0.73
  2. Xiaofei Zhang · 3 shared papers, 2022–2024 · strength 0.50
  3. Shengbai Xue · 3 shared papers, 2022–2024 · strength 0.50
  4. Jiujie Cui · 3 shared papers, 2022–2024 · strength 0.50
  5. Jing Xue · 4 shared papers, 2019–2025 · strength 0.50
  6. Ping Lu · 3 shared papers, 2019–2025 · strength 0.39
  7. Ningning Niu · 3 shared papers, 2019–2025 · strength 0.39
  8. Yanling Wang · 2 shared papers, 2023–2024 · strength 0.37
  9. Weiyu Ge · 2 shared papers, 2022–2023 · strength 0.30
  10. Zhigang Zhang · 3 shared papers, 2019–2021 · strength 0.27
  11. Yongwei Sun · 3 shared papers, 2019–2021 · strength 0.27
  12. Xuqing Shen · 1 shared paper, 2025 · strength 0.22
  13. Yingying Tang · 1 shared paper, 2025 · strength 0.22
  14. Jian‐Yu Yang · 2 shared papers, 2020–2021 · strength 0.19
  15. Xueliang Fu · 2 shared papers, 2020–2021 · strength 0.19
  16. Dejun Liu · 2 shared papers, 2020–2021 · strength 0.19
  17. Minwei Yang · 2 shared papers, 2020–2021 · strength 0.19
  18. Rong Hua · 2 shared papers, 2020–2021 · strength 0.19
  19. Yan‐Miao Huo · 2 shared papers, 2020–2021 · strength 0.19
  20. Hong Li · 1 shared paper, 2021 · strength 0.11
  21. Junfeng Zhang · 1 shared paper, 2021 · strength 0.11
  22. Wei Chiang Liu · 1 shared paper, 2021 · strength 0.11
  23. Juanjuan Shi · 1 shared paper, 2019 · strength 0.08
  24. Yuan Fang · 1 shared paper, 2019 · strength 0.08
  25. Lei Zhang · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.